Novavax Inc., a global company advancing protein-based vaccines with its Matrix-M adjuvant, was granted full marketing authorization by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK for its prototype COVID-19 vaccine Nuvaxovid (NVX-CoV2373) for individuals aged 12 and older for active immunization to help prevent COVID-19.   Authorization was based on two Phase 3 trials, PREVENT-19 conducted in the U.S. and Mexico and a Phase 3 trial in the UK, as well as a Phase 2a/...